Abbott Diabetes Care Inc v. Dexcom Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Abbott Diabetes Care Inc. (Delaware) and Abbott Diabetes Care Limited (United Kingdom)
  • Defendant: Dexcom, Inc. (Delaware)
  • Plaintiff's Counsel: Morris, Nichols, Arsht & Tunnell LLP
• Case Identification: 1:21-cv-00977, D. Del., 05/20/2022
• Venue Allegations: Venue is alleged to be proper in the District of Delaware because the defendant, Dexcom, Inc., is a Delaware corporation and therefore resides in the district.
• Core Dispute: Plaintiff alleges that Defendant's G6 line of continuous glucose monitoring (CGM) systems infringes twelve U.S. patents related to CGM technology, including methods for data processing, factory calibration, and the mechanical design of sensor inserters.
• Technical Context: Continuous glucose monitoring systems are medical devices that allow for real-time tracking of a user's glucose levels, representing a significant technological and quality-of-life improvement over traditional, intermittent fingerstick blood glucose measurements for diabetes management.
• Key Procedural History: This Second Amended Complaint follows an original complaint filed on July 2, 2021. The filing comes after the March 31, 2021 expiration of a covenant-not-to-sue, which was part of a broader Settlement and License Agreement the parties entered into in July 2014 to resolve prior litigation. The complaint alleges that Dexcom unsuccessfully sought to extend the covenant before continuing its allegedly infringing activities.

Case Timeline

Date	Event
2007-08-07	'443 Patent Priority Date
2008-04-29	'842 and '653 Patents Priority Date
2009-01-24	'954 Patent Priority Date
2010-01-28	'338 and '644 Patents Priority Date
2010-11-08	'341, '649, '654, '216, and '440 Patents Priority Date
2011-04-18	'647 Patent Priority Date
2014-07-XX	Abbott and Dexcom enter Settlement and License Agreement (SLA)
2018-XX-XX	Dexcom introduces its G6 CGM product
2020-XX-XX	Dexcom introduces its G6 Pro product
2020-11-03	'842 Patent Issued
2020-11-10	'954 Patent Issued
2020-12-29	'338 Patent Issued
2021-01-05	'341 Patent Issued
2021-03-16	'647 and '649 Patents Issued
2021-03-23	'653 Patent Issued
2021-03-30	'654 Patent Issued
2021-03-31	Covenant-not-to-sue from 2014 SLA expires
2021-04-06	'644 Patent Issued
2021-04-13	'443 Patent Issued
2021-05-11	'216 Patent Issued
2021-05-25	'440 Patent Issued
2021-07-02	Original Complaint Filed
2022-05-20	Second Amended Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 10,820,842 - "Methods and Systems for Early Signal Attenuation Detection and Processing"

• Patent Identification: U.S. Patent No. 10,820,842 ("Methods and Systems for Early Signal Attenuation Detection and Processing"), issued November 3, 2020.

The Invention Explained

• Problem Addressed: The patent addresses the issue of "data gaps" that occur in continuous glucose monitoring (CGM) systems when a "failure mode condition" prevents the system from reporting glucose levels Compl. ¶130 The complaint uses an image from a prior Dexcom system to illustrate how such gaps appear as missing data on a patient's glucose trend graph, leaving the user uninformed Compl. ¶133 These gaps can result from events like a failed calibration or other system errors, leading to a loss of valuable health information '842 Patent, col. 11:8-16
• The Patented Solution: The invention proposes a system that, upon detecting a failure mode, stores the raw, unprocessed sensor data rather than discarding it Compl. ¶137 '842 Patent, abstract Once the failure condition is resolved (e.g., via a successful new calibration), the system can then retrospectively process the stored data using the now-valid parameters and "backfill" the previously empty gap in the user's displayed glucose history, as shown in the patent's Figure 7B '842 Patent, col. 12:59-67 '842 Patent, Fig. 7B
• Technical Importance: This backfilling technology provides a more complete and accurate historical record of a patient's glucose levels, which may improve therapy and health management decisions by filling in information that would otherwise be permanently lost Compl. ¶147

Key Claims at a Glance

• The complaint asserts independent claims 1 (a method) and 14 (a system) Compl. ¶61
• Essential elements of independent claim 1 include:
  • A method of backfilling data in an analyte monitoring system.
  • Detecting a failure mode condition causing one or more sensor data gaps.
  • Storing sensor data from a time period associated with the failure mode.
  • In response to a correction of the failure mode condition, outputting the processed stored sensor data to the display.
• Essential elements of independent claim 14 include:
  • An analyte monitoring system with a sensor, processor(s), and memory.
  • Instructions stored in memory that, when executed, cause the processor(s) to detect a failure mode, store sensor data received during that mode, process the stored data, and output it to a display in response to a correction of the failure condition.
• The complaint also identifies multiple dependent claims for potential assertion Compl. ¶61

U.S. Patent No. 10,827,954 - "Continuous Analyte Measurement Systems and Methods for Implanting Them"

• Patent Identification: U.S. Patent No. 10,827,954 ("Continuous Analyte Measurement Systems and Methods for Implanting Them"), issued November 10, 2020.

The Invention Explained

• Problem Addressed: The patent background describes the inconvenience and pain of traditional glucose monitoring, which requires frequent fingerstick calibrations to ensure sensor accuracy over time '954 Patent, col. 3:1-25 The complaint alleges that earlier CGM systems, like Dexcom's G5, required users to calibrate twice daily Compl. ¶76
• The Patented Solution: The patented invention is a CGM system that is factory-calibrated and includes a pre-programmed "drift profile" in its memory '954 Patent, col. 35:1-11 This profile contains data or functions that allow the system's electronics to automatically apply a "drift correction factor" to the sensor signals over the life of the sensor, thereby maintaining accuracy without requiring user-initiated fingerstick calibrations '954 Patent, abstract '954 Patent, col. 5:58-66
• Technical Importance: Eliminating the need for routine user calibrations through factory programming represented a major step forward in making CGM technology more user-friendly, less painful, and more widely accessible Compl. ¶¶79-80

Key Claims at a Glance

• The complaint asserts independent claim 1 (a system) Compl. ¶61
• Essential elements of independent claim 1 include:
  • A continuous analyte measurement system.
  • An on-skin analyte sensor that generates signals corresponding to an analyte level.
  • A drift profile programmed into memory prior to the sensor's insertion.
  • Electronics configured to determine the analyte level using a function determined at least in part by a drift correction factor derived from the drift profile.
• The complaint also identifies multiple dependent claims for potential assertion Compl. ¶61

U.S. Patent No. 10,874,338 - "Devices, Systems and Methods for On-Skin or On-Body Mounting of Medical Devices"

• Patent Identification: U.S. Patent No. 10,874,338, "Devices, Systems and Methods for On-Skin or On-Body Mounting of Medical Devices," issued December 29, 2020.
• Technology Synopsis: The patent describes a support body for mounting a medical device to the skin that includes a breakable or weak portion. This feature is designed to facilitate easier removal of the device from the body after its use period has ended '338 Patent, abstract
• Asserted Claims: Independent claims 1, 10, and 22 are asserted Compl. ¶61
• Accused Features: The complaint targets the design of the Dexcom G6 transmitter holder and the process by which users are instructed to remove it from the sensor pod, which allegedly involves breaking it away Compl. ¶¶193-194

U.S. Patent No. 10,881,341 - "Medical Device Inserters and Processes of Inserting and Using Medical Devices"

• Patent Identification: U.S. Patent No. 10,881,341, "Medical Device Inserters and Processes of Inserting and Using Medical Devices," issued January 5, 2021.
• Technology Synopsis: This patent details an inserter for medical devices, such as a glucose sensor. It claims a mechanical assembly involving a sliding member, multiple springs, and a button-actuated trigger configured to automatically advance a sensor into the skin and subsequently retract the insertion needle in a single, user-initiated action '341 Patent, abstract
• Asserted Claims: Independent claim 1 is asserted Compl. ¶61
• Accused Features: The allegations focus on the Dexcom G6's "one-touch applicator," which the complaint describes as a simplified, automated insertion system that mimics the claimed invention (Compl. ¶96; Compl. ¶97; Compl. ¶98).

U.S. Patent No. 10,945,647 - "Analyte Sensor Transmitter Unit Configuration for a Data Monitoring and Management System"

• Patent Identification: U.S. Patent No. 10,945,647, "Analyte Sensor Transmitter Unit Configuration for a Data Monitoring and Management System," issued March 16, 2021.
• Technology Synopsis: The patent discloses an assembly for connecting an analyte sensor and a transmitter. It describes a transmitter mount with a base and a locking mechanism that secures the transmitter to the sensor subassembly, ensuring proper alignment and electrical contact '647 Patent, abstract
• Asserted Claims: Independent claim 1 is asserted Compl. ¶61
• Accused Features: The infringement allegations target the mechanical interface between the Dexcom G6 transmitter and its holder, specifically the way the transmitter "snaps in" and is secured for use Compl. ¶31 Compl. ¶234 Compl. ¶236

U.S. Patent No. 10,945,649 - "Medical Device Inserters and Processes of Inserting and Using Medical Devices"

• Patent Identification: U.S. Patent No. 10,945,649, "Medical Device Inserters and Processes of Inserting and Using Medical Devices," issued March 16, 2021.
• Technology Synopsis: This patent describes a compact sensor inserter assembly that uses a torsion spring. The claimed mechanism involves a rotor and follower that work together to advance a needle and sensor into the skin and then retract the needle '649 Patent, abstract
• Asserted Claims: Independent claim 1 is asserted Compl. ¶61
• Accused Features: The complaint alleges that the compact and "easy-to-use" design of the G6 inserter, which uses a torsion spring, incorporates the technology claimed in the '649 patent Compl. ¶¶89-90

U.S. Patent No. 10,952,653 - "Methods and Systems for Early Signal Attenuation Detection and Processing"

• Patent Identification: U.S. Patent No. 10,952,653, "Methods and Systems for Early Signal Attenuation Detection and Processing," issued March 23, 2021.
• Technology Synopsis: As a continuation of the '842 patent family, this patent also addresses the problem of data gaps in CGM systems. It claims a system that stores data during a failure mode and backfills it after correction, with specific claims directed to failure modes such as a "sensor communication error" '653 Patent, abstract Compl. ¶272
• Asserted Claims: Independent claim 1 is asserted Compl. ¶61
• Accused Features: Infringement allegations are based on the Dexcom G6's ability to backfill up to three hours of data gaps caused by a "Signal Loss" or similar issue, which the complaint equates to a "sensor communication error" Compl. ¶¶278-279

U.S. Patent No. 10,959,654 - "Medical Device Inserters and Processes of Inserting and Using Medical Devices"

• Patent Identification: U.S. Patent No. 10,959,654, "Medical Device Inserters and Processes of Inserting and Using Medical Devices," issued March 30, 2021.
• Technology Synopsis: This patent describes an automated inserter mechanism with a sliding member that moves along a straight track. The mechanism uses a first spring for insertion and a second spring for retraction, all triggered by a single button press '654 Patent, abstract
• Asserted Claims: Independent claim 1 is asserted Compl. ¶61
• Accused Features: The complaint alleges the G6's automated applicator, with its internal mechanics for insertion and retraction, infringes on the '654 patent's claims Compl. ¶89 Compl. ¶298

U.S. Patent No. 10,966,644 - "Devices, Systems and Methods for On-Skin or On-Body Mounting of Medical Devices"

• Patent Identification: U.S. Patent No. 10,966,644, "Devices, Systems and Methods for On-Skin or On-Body Mounting of Medical Devices," issued April 6, 2021.
• Technology Synopsis: Similar to the '338 patent, this patent relates to a support body for an on-body medical device. It claims a frangible area designed to break and facilitate the removal of one part of the device from another, such as detaching a reusable component from a disposable one '644 Patent, abstract
• Asserted Claims: Independent claim 1 is asserted Compl. ¶61
• Accused Features: The allegations are directed at the method of removing the reusable G6 transmitter from the disposable sensor mount, which is alleged to involve breaking a portion of the support structure Compl. ¶¶318-319

U.S. Patent No. 10,973,443 - "Sensor Inserter Assembly"

• Patent Identification: U.S. Patent No. 10,973,443, "Sensor Inserter Assembly," issued April 13, 2021.
• Technology Synopsis: The patent describes a sensor inserter device with an actuator, a shuttle, and a drive spring. The mechanism is designed to automatically advance a sensor into the skin and retract a needle upon user activation, simplifying the insertion process '443 Patent, abstract
• Asserted Claims: Independent claims 1 and 13 are asserted Compl. ¶61
• Accused Features: The complaint alleges that the G6's "automatic applicator" incorporates the claimed features to provide a simple and less painful insertion experience Compl. ¶¶87-88 Compl. ¶338

U.S. Patent No. 11,000,216 - "Medical Device Inserters and Processes of Inserting and Using Medical Devices"

• Patent Identification: U.S. Patent No. 11,000,216, "Medical Device Inserters and Processes of Inserting and Using Medical Devices," issued May 11, 2021.
• Technology Synopsis: This patent also covers an automated inserter mechanism. It claims a compact assembly with a sliding member, a button, and first and second springs configured to manage the insertion and retraction sequence along a straight track '216 Patent, abstract
• Asserted Claims: Independent claim 1 is asserted Compl. ¶61
• Accused Features: The complaint alleges the mechanical design of the G6's compact, automated inserter infringes the claims of the '216 patent Compl. ¶89 Compl. ¶358

U.S. Patent No. 11,013,440 - "Medical Device Inserters and Processes of Inserting and Using Medical Devices"

• Patent Identification: U.S. Patent No. 11,013,440, "Medical Device Inserters and Processes of Inserting and Using Medical Devices," issued May 25, 2021.
• Technology Synopsis: This patent describes a sensor inserter using a torsion spring and a rotor that interacts with a slidable body. The claimed design automates the sequence of advancing the sensor and retracting the needle with a single user action '440 Patent, abstract
• Asserted Claims: Independent claim 1 is asserted Compl. ¶61
• Accused Features: The complaint alleges that the G6 inserter, which it claims is a "convenient, easy-to-use, compact, automated" device using a torsion spring, infringes the '440 patent Compl. ¶90 Compl. ¶378

III. The Accused Instrumentality

• Product Identification: The accused instrumentalities are the "Dexcom G6 Continuous Glucose Monitoring system and variations thereof, including Dexcom Pro Q Continuous Glucose Monitoring System, Dexcom G6 Pro Continuous Glucose Monitoring System, and Dexcom G6 ONF Continuous Glucose Monitoring System" (collectively, the "Accused Products") Compl. ¶62
• Functionality and Market Context: The Accused Products are continuous glucose monitoring systems marketed for diabetes management Compl. ¶29 The complaint describes the G6 system as comprising three main components: a sensor with a built-in applicator, a transmitter, and a display device (such as a dedicated receiver or a smart device running a compatible app) Compl. ¶30 A diagram from the G6 user guide included in the complaint illustrates these components and their functions Compl. ¶30 Key functionalities targeted by the complaint include the system's factory calibration, which eliminates the need for routine fingerstick calibrations by the user; its automated, single-press sensor applicator; and its ability to "backfill" data gaps that occur from temporary signal loss (Compl. ¶¶33; Compl. ¶97; Compl. ¶149). The complaint positions the G6 as a direct competitor to Abbott's FreeStyle Libre products and as a significant departure from Dexcom's previous G5 product, which required fingerstick calibrations and had a more complex insertion process Compl. ¶¶29, 33-34

IV. Analysis of Infringement Allegations

The complaint references Initial Claim Charts in Appendices A-L, which are incorporated by reference but not attached to the complaint document Compl. ¶64 As the charts are not provided, the infringement allegations are summarized below in prose based on the narrative in the complaint.

• U.S. Patent No. 10,820,842 Infringement Allegations:
  The complaint alleges that the Accused Products infringe the '842 patent through their "backfill" feature Compl. ¶149 It states that when the G6 receiver and transmitter lose connection, a data gap can occur; however, upon reconnection, "up to 3 hours of missed G6 readings can fill in on the graph" Compl. ¶154 The complaint includes a screenshot from the G6 User Guide to support this allegation, which explicitly states this backfilling capability Compl. ¶154 This functionality of storing data during a communication loss (the alleged "failure mode condition") and later displaying it upon reconnection is alleged to meet the limitations of claims 1 and 14 Compl. ¶¶143-144 Compl. ¶150

• U.S. Patent No. 10,827,954 Infringement Allegations:
  The complaint alleges infringement of the '954 patent based on the G6's factory calibration and "no fingersticks" feature Compl. ¶¶79-80 The theory of infringement is that the G6 system relies on a pre-programmed "drift profile" as claimed. Evidence cited includes the G6 User Guide, which instructs users to enter a unique sensor code from the applicator to use the G6 without fingerstick calibrations Compl. ¶174 An image from the guide illustrates this code entry step Compl. ¶174 The complaint alleges this code provides the system with the necessary factory-determined information to implement a "drift correction factor" to maintain accuracy over the sensor's life, thereby meeting the elements of claim 1 Compl. ¶170

• Identified Points of Contention:

  • Scope Questions: A primary point of contention for the '842 patent will likely be the definition of "failure mode condition." The court may need to decide if a routine and expected temporary loss of wireless signal constitutes a "failure" in the sense claimed by the patent, which describes examples such as calibration errors and system malfunctions '842 Patent, col. 13:19-27 For the '954 patent, a central question will be whether the G6's "sensor code" system is equivalent in scope to the claimed "drift profile," which the patent describes as potentially being derived from analyzing a plurality of sensors over time '954 Patent, col. 3:52-55
  • Technical Questions: A technical question for the '842 patent is whether the simple re-transmission of stored data points in the G6 constitutes the claimed step of "processing" the stored data in response to the correction of the failure mode, as the patent suggests this processing could involve using updated calibration parameters '842 Patent, col. 12:47-54 For the '954 patent, a technical question is how the G6 system actually uses the sensor code-whether it simply provides initial calibration parameters or functions as a dynamic "drift correction factor" throughout the sensor's wear period as claimed.

V. Key Claim Terms for Construction

• Term 1 ('842 Patent): "failure mode condition"

  • The Term: "failure mode condition"
  • Context and Importance: This term's scope is critical for infringement of the '842 patent. Abbott's case appears to depend on this term covering the temporary "Signal Loss" that occurs in the accused G6 system Compl. ¶154 The definition will determine whether routine communication interruptions fall within the patent's scope.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The claims do not define the term, leaving it open to a broader, plain-meaning interpretation. The specification uses permissive language, stating a failure mode condition "may include one or more" of a list of examples, suggesting the list is not exhaustive '842 Patent, col. 13:19-27
    • Evidence for a Narrower Interpretation: The specification provides a list of relatively specific and significant system errors as examples of a "failure mode condition," including "an inability to promptly calibrate the sensor, system malfunction, sensor dislodging, signal errors associated with the sensor, transmitter unit, receiver unit," and "a sensor calibration event" '842 Patent, col. 13:19-27 '842 Patent, col. 11:8-9 A defendant may argue that these examples cabin the term's meaning to actual malfunctions, not predictable, temporary disconnections.

• Term 2 ('954 Patent): "drift profile"

  • The Term: "drift profile"
  • Context and Importance: The infringement argument for the '954 patent hinges on mapping the accused G6's "sensor code" feature to this claim term. Practitioners may focus on this term because its construction will determine whether a system that uses a one-time code for factory calibration practices the claimed invention of using a pre-programmed "profile" to correct for drift over time.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The patent specification provides a broad definition, stating a drift profile "may be a single value, a series of values, a function, or a set of functions" that is used to correct for sensor drift '954 Patent, col. 5:64-66 This could support an argument that the information conveyed by the G6's sensor code falls within this definition.
    • Evidence for a Narrower Interpretation: The specification also describes an embodiment where the drift profile is determined by "analyzing signals from a plurality of sensors over a period of time during the manufacturing process" '954 Patent, col. 3:52-55 A defendant may argue this implies a more complex, time-based characterization of sensor degradation than what may be represented by a single calibration code.

VI. Other Allegations

• Indirect Infringement: The complaint alleges both induced infringement under 35 U.S.C. § 271(b) and contributory infringement under § 271(c) for all twelve asserted patents Compl. ¶¶66-67 The basis for inducement is the allegation that Dexcom actively and knowingly encourages infringement by providing user guides, marketing materials, and other documentation that instruct patients and physicians on how to use the Accused Products in an infringing manner Compl. ¶118 The contributory infringement claim is based on the allegation that the components of the Accused Products are not staple articles of commerce and are especially made or adapted for practicing the patented inventions Compl. ¶119
• Willful Infringement: Willfulness is alleged based on both pre-suit and post-suit knowledge Compl. ¶¶121-123 The complaint alleges Dexcom knew of Abbott's patented technology due to being a "fierce rival" and was aware of the Asserted Patents "on or shortly after the dates on which they issued" Compl. ¶¶69-70 Crucially, the complaint highlights the parties' prior litigation history and the expiration of a covenant-not-to-sue, arguing Dexcom proceeded to infringe "unabatedly" with actual knowledge after the covenant expired, despite its requests for an extension being denied Compl. ¶¶113-115 Notice via the original complaint in this action is also cited as a basis for ongoing willful infringement Compl. ¶72

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of definitional scope and technical equivalency: Can the term "failure mode condition" from the '842 patent, which the specification illustrates with calibration errors and system malfunctions, be construed to cover the routine "Signal Loss" and data backfilling feature of the accused G6 system? Similarly, does the "sensor code" used by the G6 function as the claimed "drift profile" of the '954 patent, or is there a fundamental mismatch in technical operation?
• A second central battle will concern the mechanics of infringement: With a majority of the asserted patents relating to the mechanical design of sensor inserters, a key question will be whether Abbott can prove that the single design of the G6 auto-applicator infringes the specific and varied elements recited across numerous distinct mechanical patents, or if Dexcom can successfully distinguish its product from each claimed configuration.
• A key evidentiary question will relate to intent and damages: The case's history, including a prior settlement and an expired covenant-not-to-sue, will be a focal point. The court will likely examine whether Dexcom's decision to launch and sell products with allegedly infringing features after the covenant expired constitutes willful infringement, an issue that could significantly impact any potential damages award.